English
Home > Products > CAS NO 41036-19-5

China CAS NO 41036-19-5 Factory

No matter new customer or old customer, We believe in long term and trusted relationship for CAS NO 41036-19-5,41036-19-5,H-ALA-ALA-OME HCL, Prospects first! Whatever you require, we should do our utmost to help you. We warmly welcome clients from all around the globe to cooperate with us for mutual enhancement.
CAS NO 41036-19-5, As operation principle is "be market-oriented , good faith as principle, win-win as objective", holding on "customer first, quality assurance, service first" as our purpose, dedicated to offer the original quality, create excellence service , we won the praise and trust in the industry of auto parts. In the future, We are going to give quality product and excellent service in return to our customers , welcome any suggestions and feedback from all over the world.

Related Products

Hot Products

  • Ceftizoxime

    Ceftizoxime

    Product Name:Ceftizoxime
    Molecular Formula:C13H13N5O5S2
    Molecular Weight;383.4
    CAS Registry Number;68401-81-0
  • Phenylboronic Acid

    Phenylboronic Acid

    Product Name:Phenylboronic Acid
    Molecular Weight:121.93
    CAS Registry Number:98-80-6
  • Alogliptin benzoate

    Alogliptin benzoate

    Product Name:Alogliptin benzoate
    Molecular Formula:C25H27N5O4
    Molecular Weight;461.52
    CAS Registry Number;850649-62-6
  • Methyl trifluoroacetate

    Methyl trifluoroacetate

    Product Name:Methyl trifluoroacetate
    Molecular Formula:C3H3F3O2
    Molecular Weight:128.05
    CAS Registry Number:431-47-0
  • Fmoc-His(Trt)-OH

    Fmoc-His(Trt)-OH

    Product Name:Fmoc-His(Trt)-OH
    Molecular Formula:C40H33N3O4
    Molecular Weight:619.71
    CAS Registry Number:109425-51-6
  • cis-Octahydroisoindole

    cis-Octahydroisoindole

    Product Name:cis-Octahydroisoindole
    Molecular Formula:C8H15N
    Molecular Weight:125.21
    CAS Registry Number:1470-99-1/21850-12-4
  • Related Blog
  • Reviews

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • How is a drug produced?

    ​There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept